



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 04/21/2022 17:40
Last Report Issued 01/14/2019 06:54

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 2504SP
Patient ID 2504SP
Chain 19000127
DOB Not Given
Sex Not Given
Workorder 19000127
Received 01/14/2019

Lab ID 19000127-001
Matrix Serum or Plasma
Patient Name 2504SP
Patient ID 2504SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes Not frozen as required

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

2504SP Levodopa, Serum/Plasma

Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Levodopa	None Detected	mcg/mL	0.020	
----------	---------------	--------	-------	--

The target plasma concentration of levodopa in Parkinsonian patients is 2 +/- 0.5 mcg/mL. The average peak plasma levodopa concentration following a single oral dose of Sinemet® containing 200 mg levodopa was 1.2 mcg/mL at 0.5 hours for normal release and 3.3 mcg/mL at 2 hours for controlled release. At steady-state, the average trough plasma levodopa concentration following oral Sinemet® containing 200 mg levodopa was 0.07 mcg/mL for normal release and 0.16 mcg/mL for controlled release.

Sample receipt condition is inappropriate for test code: Not frozen as required

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.